767 reports of this reaction
4.7% of all BLEOMYCIN SULFATE reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for BLEOMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 767 FDA adverse event reports linking BLEOMYCIN SULFATE to OFF LABEL USE. This represents approximately 4.7% of all 16,267 adverse event reports for this drug.
Patients taking BLEOMYCIN SULFATE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among BLEOMYCIN SULFATE users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for BLEOMYCIN SULFATE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 767 FDA reports for BLEOMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 4.7% of all adverse event reports for BLEOMYCIN SULFATE, making it one of the most commonly reported side effect.
If you experience off label use while taking BLEOMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.